HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $5.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Leap Therapeutics (NASDAQ:LPTX) and maintained a price target of $5.5.
August 13, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Leap Therapeutics and maintained a price target of $5.5.
The reiteration of a Buy rating and the maintenance of a $5.5 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100